JW (Cayman) Therapeutics Co Ltd - ESG Rating & Company Profile powered by AI
If you are employed by JW (Cayman) Therapeutics Co Ltd and you would like to licence your Sustainability aseessment, please get in touch. Check the bottom of the webpage for potential risks for JW (Cayman) Therapeutics Co Ltd based on sector, location and size. This analysis of JW (Cayman) Therapeutics Co Ltd incorporates information from across the internet and also from public disclosures by JW (Cayman) Therapeutics Co Ltd.
JW (Cayman) Therapeutics Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.8; made up of an environmental score of 2.0, social score of 4.8 and governance score of 1.6.
2.8
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1353 | Vera Therapeutics Inc | 2.9 | Medium |
1353 | Veracyte Inc | 2.9 | Medium |
1393 | JW (Cayman) Therapeutics Co Ltd | 2.8 | Medium |
1393 | Bioventix PLC | 2.8 | Medium |
1393 | Bolt Biotherapeutics Inc | 2.8 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does JW (Cayman) Therapeutics Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Does JW (Cayman) Therapeutics Co Ltd disclose current and historical energy intensity?
Does JW (Cayman) Therapeutics Co Ltd report the average age of the workforce?
Does JW (Cayman) Therapeutics Co Ltd reference operational or capital allocation in relation to climate change?
Does JW (Cayman) Therapeutics Co Ltd disclose its ethnicity pay gap?
Does JW (Cayman) Therapeutics Co Ltd disclose cybersecurity risks?
Does JW (Cayman) Therapeutics Co Ltd offer flexible work?
Does JW (Cayman) Therapeutics Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does JW (Cayman) Therapeutics Co Ltd disclose the number of employees in R&D functions?
Does JW (Cayman) Therapeutics Co Ltd conduct supply chain audits?
Does JW (Cayman) Therapeutics Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does JW (Cayman) Therapeutics Co Ltd conduct 360 degree staff reviews?
Does JW (Cayman) Therapeutics Co Ltd disclose the individual responsible for D&I?
Does JW (Cayman) Therapeutics Co Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does JW (Cayman) Therapeutics Co Ltd disclose current and / or historical scope 2 emissions?
Does JW (Cayman) Therapeutics Co Ltd disclose water use targets?
Does JW (Cayman) Therapeutics Co Ltd have careers partnerships with academic institutions?
Did JW (Cayman) Therapeutics Co Ltd have a product recall in the last two years?
Does JW (Cayman) Therapeutics Co Ltd disclose incidents of discrimination?
Does JW (Cayman) Therapeutics Co Ltd allow for Work Councils/Collective Agreements to be formed?
Has JW (Cayman) Therapeutics Co Ltd issued a profit warning in the past 24 months?
Does JW (Cayman) Therapeutics Co Ltd disclose parental leave metrics?
Does JW (Cayman) Therapeutics Co Ltd disclose climate scenario or pathway analysis?
Does JW (Cayman) Therapeutics Co Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does JW (Cayman) Therapeutics Co Ltd disclose the pay ratio of women to men?
Does JW (Cayman) Therapeutics Co Ltd support suppliers with sustainability related research and development?
Does JW (Cayman) Therapeutics Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does JW (Cayman) Therapeutics Co Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is JW (Cayman) Therapeutics Co Ltd involved in embryonic stem cell research?
Does JW (Cayman) Therapeutics Co Ltd disclose GHG and Air Emissions intensity?
Does JW (Cayman) Therapeutics Co Ltd disclose its waste policy?
Does JW (Cayman) Therapeutics Co Ltd report according to TCFD requirements?
Does JW (Cayman) Therapeutics Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does JW (Cayman) Therapeutics Co Ltd disclose energy use targets?
Does JW (Cayman) Therapeutics Co Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does JW (Cayman) Therapeutics Co Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for JW (Cayman) Therapeutics Co Ltd
These potential risks are based on the size, segment and geographies of the company.
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is relmacabtagene autoleucel, an anti-CD19 CAR-T therapy for relapsed or refractory B-cell lymphoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.